Kyverna Therapeutics, Inc.
KYTX
$3.78
-$0.03-0.79%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -46.10% | -67.22% | -81.40% | -- | -- |
| Total Depreciation and Amortization | -2.83% | 3.94% | 21.86% | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 548.39% | -44.41% | -126.70% | -- | -- |
| Change in Net Operating Assets | 86.64% | -18.82% | -96.63% | -- | -- |
| Cash from Operations | -32.16% | -75.96% | -99.65% | -146.94% | -- |
| Capital Expenditure | 99.61% | -- | -59.28% | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 143.61% | 104.56% | -7.06% | -- | -- |
| Cash from Investing | 142.94% | 104.54% | -7.76% | 101.25% | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -11.02% | -47.62% | -12.79% | -- | -- |
| Issuance of Common Stock | -100.00% | -100.00% | -88.36% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 17.24% | 97.43% | 100.00% | -- | -- |
| Cash from Financing | -14.06% | -100.12% | 85.01% | -100.44% | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 96.30% | -120.96% | -168.93% | 11.47% | -- |